Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
97 participants
INTERVENTIONAL
2020-01-01
2023-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia
NCT04507815
TDCS as Augmentation Therapy to Cognitive Training in Mild Dementia
NCT06559254
A Pilot Study of tDCS for Mild Cognitive Impairment
NCT02227966
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
NCT04599764
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
NCT04121156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tDCS+DAOIB
DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
tDCS
tDCS
tDCS+placebo
Placebo
placebo
tDCS
tDCS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Placebo
placebo
tDCS
tDCS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MMSE between 10-26
* CDR 1 or 0.5
Exclusion Criteria
* Substance abuse/dependence
* Parkinson disease, epilepsy, dementia with psychotic features
* Major depressive disorder
* Major physical illnesses
* Severe visual or hearing impairment
50 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chang Gung Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201601789A0C603
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.